2024/7/24 该公司公布和辉瑞合作开发血友病基因药物三期达标,股价暴涨,后续可期!查看全文
产业链观察07-24 21:24
#药闻简讯# 2024 年 7 月 24 日,$辉瑞(PFE)$ 今天宣布了评估giroctocogene fitelparvovec的3期研究(NCT04370054)的积极顶线结果,该研究是一种用于治疗中度至重度血友病A成人的研究性基因疗法。$Sangamo Therapeutics(SGMO)$查看全文
Sangamo Therapeutics(SGMO)2023-11-04 04:05
$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-23-036697 Act: 34 Size: 1 MB 网页链接查看全文
Sangamo Therapeutics(SGMO)2023-08-09 04:55
$Sangamo Therapeutics(SGMO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-23-206301 Act: 33 Size: 73 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2023-08-30 04:25
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-047586 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2023-08-30 04:25
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-047590 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)01-25 05:45
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001756 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)01-25 05:45
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001754 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)01-25 05:45
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001755 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)04-20 04:25
$Sangamo Therapeutics(SGMO)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-102893 Act: 34 Size: 17 MB 网页链接查看全文
空之客2020-08-20 16:25
回复@Stevevai1983: 我看到的数可不是低了一点,Ph3在23-26周的F8水平比Ph1/2高剂量组在同一时期少了快一半。
2019年5月公布的Ph3 topline data说,在23-26周时有8位(一共16位)受试者的F8浓度超过40IU/dL,平均值在36;而2020年6月公布的Ph1/2 4 year data说,在高剂量组(跟Ph3相同)23-26...查看全文
空之客2020-08-20 00:16
Double kill!$拜玛林制药(BMRN)$ 的AAV5治疗A型血友病也收到了FDA的CRL,认为3期临床中期数据与1/2期临床数据存在差异,因此出于更谨慎的考虑要求完成3期临床的2年随访。
网页链接查看全文
chuminhua2020-06-26 22:35
6/24,Sangamo$Sangamo Therapeutics(SGMO)$ 宣布将拆分研究和开发成为两个“独立的只能”,另外,将寻找新的开发业务负责人。研究业务将由细胞疗法的高级副总裁Jason Fontenot暂时负责。去年1月加入的研发负责人,前Pfizer高管 Adrian Woolfson将离职。查看全文
chuminhua2020-06-21 12:08
6/18,Pfizer$辉瑞(PFE)$ 和Sangamo$Sangamo Therapeutics(SGMO)$ 在WFH World Congress 2020上发布了更新的A型血友病基因疗法giroctocogene fitelparvovec(SB-525)的I/II期数据。5名 患者接受了最高剂量3e13 vg/kg。治疗时间最长的患者显示出长达44周的持续VIII因子活性。查看全文
逍遥谷-百奥生2020-06-11 23:38
小药股,去伪存真,耐心等待,机会会再次降临。
$Sangamo Therapeutics(SGMO)$ $Cellectis(CLLS)$ $Autolus Therapeutics(AUTL)$.
需要的是找到潜力巨大,爆发力强的个股。欢迎朋友们补充。查看全文
智通财经APP获悉,近期,RBC针对Verrica Pharmaceuticals(VRCA.US)、Sangamo Therapeutics(SGMO.US)、GooseHead Insurance(GSHD.US)三家公司发表研报,并强调了这三只股票未来强劲的长期增长前景,预计在未来一年的上行空间将至少达到50... 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-24-032815 Act: 34 Size: 287 KB 网页链接
$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001086364-24-008122 Act: 34 Size: 12 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016686 Size: 6 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015752 Size: 8 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015753 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015754 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015755 Size: 8 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 5.02, 5.03, 5.07, and 9.01 Accession Number: 0001628280-24-026903 Act: 34 Size: 13 MB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014796 Size: 9 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014798 Size: 9 KB 网页链接